Genetic and genomic approaches to explore roles for the conserved 3′-5′ exoribonuclease EXOSC10 in normal and malignant cells
Abstract
EXOSC10 is a conserved 3'-5' exoribonuclease involved in processing ribosomal RNAs and degrading coding and noncoding transcripts as a catalytic subunit of the nuclear RNA exosome and in cooperation with cofactors. The protein is posttranslationally modified and shuttles between the nucleolus and the nucleus in response to oxygen deprivation in a process that involves sumoylation. EXOSC10 is of medical interest because its activity is inhibited by the anticancer drug 5-fluorouracil, which interferes with DNA replication and RNA-dependent processes. Moreover, high expression of EXOSC10 in certain somatic tumors is associated with patient survival. We discuss global and tissue-specific deletion experiments in the mouse, assess the protein's clinical relevance as a prognostic cancer biomarker in the context of human genomics data for normal versus malignant tissues, and explore EXOSC10's transcriptional regulatory network.
Related
- Genomic and Transcriptomic Analysis of Nine Resurrection Plant Species: Conserved Regulation Versus Structural Paralog Capacity in Desiccation Tolerance
- Mechanochemical coupling in lung cancer: how tissue tension drives genomic instability and malignant progression
- Novel Therapeutic Targets and Approaches, Genetic Markers and Signaling Pathways in Neoplasms—An Overview
- Recurrent tandem duplication of a conserved enhancer underlies parallel genetic origins of rumplessness in chickens
- New genetic tools in Finegoldia magna identify a conserved adhesin required for the formation of stress-tolerant aggregates
BibTeX
@article{sain2026genetic,
title = {{Genetic and genomic approaches to explore roles for the conserved 3′-5′ exoribonuclease EXOSC10 in normal and malignant cells}},
author = {Radhika Sain and Julian Primig and Michael Primig},
journal = {RNA},
year = {2026},
month = oct,
doi = {10.1261/rna.080981.126},
url = {https://hal.science/hal-05643064v1},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Genetic and genomic approaches to explore roles for the conserved 3′-5′ exoribonuclease EXOSC10 in normal and malignant cells
AU - Radhika Sain
AU - Julian Primig
AU - Michael Primig
PY - 2026
DA - 2026/10/13
JO - RNA
DO - 10.1261/rna.080981.126
UR - https://hal.science/hal-05643064v1
AB - EXOSC10 is a conserved 3'-5' exoribonuclease involved in processing ribosomal RNAs and degrading coding and noncoding transcripts as a catalytic subunit of the nuclear RNA exosome and in cooperation with cofactors. The protein is posttranslationally modified and shuttles between the nucleolus and the nucleus in response to oxygen deprivation in a process that involves sumoylation. EXOSC10 is of medical interest because its activity is inhibited by the anticancer drug 5-fluorouracil, which interferes with DNA replication and RNA-dependent processes. Moreover, high expression of EXOSC10 in certain somatic tumors is associated with patient survival. We discuss global and tissue-specific deletion experiments in the mouse, assess the protein's clinical relevance as a prognostic cancer biomarker in the context of human genomics data for normal versus malignant tissues, and explore EXOSC10's transcriptional regulatory network.
SN - 1355-8382
SN - 1469-9001
ER -